Novartis AG/€NOVN
1D1W1MYTD1Y5YMAX
Capital at risk
About Novartis AG
Novartis AG is a global healthcare company based in Switzerland, specializing in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's core business is centered around patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis operates in over 150 countries worldwide. Its strategic positioning is reinforced by significant investments in research and development, supporting a robust pipeline of innovative therapies. The company is headquartered in Basel, Switzerland, and emphasizes its competitive strength through advanced research capabilities and a diverse product portfolio.
- Ticker
- €NOVN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 75,267
- Headquarters
- Basel, Switzerland
- Website
- www.novartis.com
Novartis AG Metrics
BasicAdvanced
€226B
20.74
€5.70
0.49
€4.09
3.46%
Price and volume
Market cap
€226B
Beta
0.49
52-week high
€144.30
52-week low
€102.40
Average daily volume
2.6M
Dividend rate
€4.09
Financial strength
Current ratio
0.862
Quick ratio
0.55
Long term debt to equity
93.339
Total debt to equity
116.85
Dividend payout ratio (TTM)
71.08%
Interest coverage (TTM)
13.36%
Profitability
EBITDA (TTM)
19,898.927
Gross margin (TTM)
74.98%
Net profit margin (TTM)
22.50%
Operating margin (TTM)
32.75%
Effective tax rate (TTM)
17.88%
Revenue per employee (TTM)
€646,120
Management effectiveness
Return on assets (TTM)
10.25%
Return on equity (TTM)
30.35%
Valuation
Price to earnings (TTM)
20.738
Price to revenue (TTM)
4.629
Price to book
5.13
Price to tangible book (TTM)
-7.81
Price to free cash flow (TTM)
17.328
Free cash flow yield (TTM)
5.77%
Free cash flow per share (TTM)
6.82
Dividend yield (TTM)
3.46%
Forward dividend yield
3.46%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-3.43%
3-year revenue growth (CAGR)
8.37%
10-year revenue growth (CAGR)
1.32%
3-year earnings per share growth (CAGR)
22.59%
10-year earnings per share growth (CAGR)
8.97%
3-year dividend per share growth (CAGR)
10.48%
10-year dividend per share growth (CAGR)
5.64%
Bulls say / Bears say
Net sales rose 3% to $14.41 billion in Q2 2026, driven by strong growth in priority brands—Kisqali (+43% cc), Kesimpta (+32% cc), Scemblix (+89% cc), Pluvicto (+43% cc), and Leqvio (+59% cc)—demonstrating robust portfolio momentum. (Novartis)
Novartis repurchased 13.8 million shares for $2.1 billion in Q2 2026 under its $10 billion share buyback program, reflecting strong cash generation and commitment to shareholder returns. (Novartis)
In the US, generic competition for Entresto and Promacta offset growth, contributing to flat core operating income and a 70 basis‐point margin contraction in Q2 2026. (Novartis)
Net income fell 19% to $3.26 billion and free cash flow declined 12% to $5.56 billion in Q2 2026, underscoring near‐term profitability and cash flow headwinds. (Novartis)
Management cautioned that one‐off benefits boosting Q2 results will reverse as research and launch spending increases in H2 2026, signaling potential profit headwinds. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing Novartis AG
AllEURGBPUSD
Fund name | Fund size | €NOVN weighting |
|---|---|---|
Vanguard FTSE Developed Europe ex UK€VERX | €3.4B | 2.57% |
Vanguard FTSE Developed Europe ex UK£VERX | £2.9B | 2.57% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 2.24% |
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 2.15% |
Vanguard FTSE Developed Europe£VEUA | £2.6B | 2.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.